GENE PRODUCTS DIFFERENTIALLY EXPRESSED IN CANCEROUS CELLS

• US 20100233187A1
• Filed: 03/16/2010
• Published: 09/16/2010
• Est. Priority Date: 06/02/2000
• Status: Active Grant

• Current Assignee: Christoph Reinhard, Edward J. Moler, Filippo Randazzo, George Lamson, Giulia C. Kennedy, Jaime Escobedo, Joerg Kaufmann, Julie Sudduth-Klinger, Pablo Dominguez Garcia, Rhonda Hansen, Vivien W. Chan
• Original Assignee: Christoph Reinhard, Edward J. Moler, Filippo Randazzo, George Lamson, Giulia C. Kennedy, Jaime Escobedo, Joerg Kaufmann, Julie Sudduth-Klinger, Pablo Dominguez Garcia, Rhonda Hansen, Vivien W. Chan
• Inventors: Kaufmann, Joerg, Reinhard, Christoph, Chan, Vivien W., Kennedy, Giulia C., Hansen, Rhonda, Randazzo, Filippo, Moler, Edward J., Lamson, George, Garcia, Pablo Dominguez, Escobedo, Jaime, Sudduth-Klinger, Julie
• Granted Patent: US 8,221,983 B2
• Time in Patent Office: Days
• US Class Current: 424/174.100
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.

Claims

1. A method for inhibiting a cancerous phenotype of a cell, said method comprising:

contacting a cancerous mammalian cell with an agent for inhibition of a product of a gene identified by any of SEQ ID NOS;

1-13996.

2. The method of claim 1, wherein said cell is a breast cell.

3. The method of claim 1, wherein said cancerous phenotype is aberrant cellular proliferation relative to a normal cell.

4. The method of claim 1, wherein said cancerous phenotype is loss of contact inhibition of cell growth.

5. The method of claim 1, wherein said agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

6. The method of claim 1, wherein said inhibition is associated with a reduction in a level of protein encoded by a gene identified by any of SEQ ID NOS:

1-13996.

7. The method of claim 1, wherein said inhibition is associated with a reduction in a level of an RNA encoded by a gene identified by any of SEQ ID NOS:

1-13996.

8. The method of claim 1, wherein said inhibition is associated with a reduction in a level of activity of a protein encoded a gene identified by any of SEQ ID NOS:

1-13996.

9. A method for detecting a cancerous cell, said method comprising:

detecting a level of a product of a gene identified by any of SEQ ID NOS;

1-13996 or fragment thereof in a test sample obtained from a cell of a subject,

comparing the level of said gene product to a control level of said gene product, wherein the presence of a cancerous cell is indicated by detection of said level and comparison to said control level.

10. The method of claim 9, wherein said cancerous cell is a cancerous breast cell.

11. The method of claim 9, wherein said gene product is nucleic acid.

12. The method of claim 9, wherein said gene product is a polypeptide.

13. The method of claim 9, wherein said detecting step uses a polymerase chain reaction.

14. The method of claim 9, wherein said detecting step uses hybridization.

15. The method of claim 9, wherein said sample is a sample of breast tissue.

16. The method of claim 9, wherein said level of said product is indicative of the cancerous state of the cell of the test sample.

17. A method of treating a subject with cancer, said method comprising:

administering to a subject a pharmaceutically effective amount of an agent,

wherein said agent modulates the activity of a product of a gene identified by any of SEQ ID NOS;

1-13996.

18. The method of claim 17, wherein said cancer is breast cancer.

19. The method of claim 17, wherein said agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

20. A method for assessing the tumor burden of a subject, said method comprising:

detecting a level of a product of a gene identified by any of SEQ ID NOS;

1-13996 in a test sample from a subject,

wherein the level of said gene product in the test sample is indicative of the tumor burden in the subject.

21. A method for identifying an agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:

contacting a candidate agent with a product of a gene identified by any of SEQ ID NOS;

1-13996; and

detecting modulation of a biological activity of said product relative to a level of biological activity in the absence of the candidate agent.

22. The method of claim 21, wherein said cancerous cell and said normal cell are breast cells.

23. The method of claim 21, wherein said detecting is by assessing expression of said gene product.

24. The method of claim 23, wherein expression is assessed by detecting a polynucleotide gene product.

25. The method of claim 23, wherein expression is assessed by detecting a polypeptide gene product.

26. The method of claim 21, wherein said candidate agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

27. The method of claim 21, wherein said biological activity is modulation of a cancerous phenotype.

28. The method of claim 27, wherein said cancerous phenotype is abnormal cellular proliferation.

29. The method of claim 27, wherein said cancerous phenotype is loss of contact inhibition.